About
Peptide treatment for acute lung injury
Areas of Focus
Categories
Gene Therapy, RNA & Peptide TherapyNJ, NY, PA
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
0
As Collaborator
2
Total Enrollment
184
By Phase
PHASE3: 1
By Status
RECRUITING: 1COMPLETED: 1
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT07125079Collaborator
Lung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. These Patients Will be Monitored for: 1) Immune Cell Activation 2) Blood-based Biomarkers. In Vitro Models Derived From These Samples Will be Treated With Novel Agent PIP-2 to Evaluate Its Efficacy.
N/ARecruiting
36 participants
Started: May 20, 2025 · Completed: Nov 20, 2026
NCT00383734Collaborator
Safety and Efficacy of Intradermal Injections of Newfill Versus Eutrophill in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132 SMILE
PHASE3Completed
148 participants
Started: Dec 31, 2006 · Completed: Sep 30, 2010
Locations (1)
Headquarters
Philadelphia, PA, United States
Map
Loading map...